Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan.
Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman, Jordan.
Qual Life Res. 2021 May;30(5):1417-1424. doi: 10.1007/s11136-020-02726-9. Epub 2021 Jan 1.
The study aim was to evaluate HRQOL and to explore the variables associated with poor HRQOL among patients with dyslipidemia in Jordan.
The present study utilized the EQ-5D questionnaire which evaluates HRQOL in terms of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses to the five dimensions were presented using the value set, which ranges from 1 for full health to - 0.594 for severe problems in all five dimensions. Multiple linear regression analysis was implemented to identify the variables that best predicted the total EQ-5D score and hence HRQOL in the study population.
The mean age of the 228 participants was 60.23 (SD = 10.64). The mean of the total EQ-5D score was 0.675 (SD = 0.14). Regression analysis identified necessity for dyslipidemia medication (B = 0.18, P < 0.01) and patients with controlled lipid profile (B = 0.28, P < 0.01) were positively associated with HRQOL, while having concerns about dyslipidemia medications (B = - 0.16, P < 0.01), number of medication (B = - 0.13, P = 0.02), duration of dyslipidemia (B = - 0.22, P < 0.01), receiving high-intensity statin (B = - 0.18, P < 0.01) or statin in combination with fibrate (B = - 0.15, P < 0.01) were associated with lower HRQOL.
HRQOL has considerable scope for improvement in patients with dyslipidemia in Jordan. Improving dyslipidemia medications' beliefs and simplifying medication regimen by prescribing less medications, particularly for patients with longer disease duration and those on statin therapy, should be considered in future management programs aim at improving HRQOL in patients with dyslipidemia.
本研究旨在评估约旦血脂异常患者的健康相关生活质量(HRQOL),并探讨与 HRQOL 较差相关的变量。
本研究采用 EQ-5D 问卷评估 HRQOL,包括移动性、自理能力、日常活动、疼痛/不适以及焦虑/抑郁五个方面。五个维度的反应采用价值量表表示,范围从 1(完全健康)到 -0.594(五个维度均存在严重问题)。采用多元线性回归分析确定能够最佳预测研究人群中 EQ-5D 总分和 HRQOL 的变量。
228 名参与者的平均年龄为 60.23(SD=10.64)岁。总 EQ-5D 评分的平均值为 0.675(SD=0.14)。回归分析确定,需要血脂异常药物治疗(B=0.18,P<0.01)和血脂控制良好的患者(B=0.28,P<0.01)与 HRQOL 呈正相关,而对血脂异常药物的担忧(B=-0.16,P<0.01)、药物数量(B=-0.13,P=0.02)、血脂异常持续时间(B=-0.22,P<0.01)、接受高强度他汀类药物(B=-0.18,P<0.01)或他汀类药物联合贝特类药物(B=-0.15,P<0.01)与较低的 HRQOL 相关。
约旦血脂异常患者的 HRQOL 有相当大的改善空间。在未来的管理计划中,应考虑改善血脂异常药物的信念和简化药物治疗方案,减少药物的使用,特别是对于疾病持续时间较长和接受他汀类药物治疗的患者,以改善血脂异常患者的 HRQOL。